The estimated Net Worth of Julian S Gangolli is at least 304 千$ dollars as of 20 May 2024. Mr. Gangolli owns over 20,000 units of Revance Therapeutics Inc stock worth over 131,600$ and over the last 8 years he sold RVNC stock worth over 0$. In addition, he makes 172,300$ as Independent Director at Revance Therapeutics Inc.
Sign up
Mr. Gangolli RVNC stock SEC Form 4 insiders trading
Julian has made over 3 trades of the Revance Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of RVNC stock worth 455,000$ on 20 May 2024.
The largest trade he's ever made was exercising 671,928 units of Revance Therapeutics Inc stock on 10 May 2019 worth over 1,518,557$. On average, Julian trades about 24,248 units every 66 days since 2016. As of 20 May 2024 he still owns at least 20,000 units of Revance Therapeutics Inc stock.
You can see the complete history of Mr. Gangolli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Julian Gangolli biography
Julian S. Gangolli serves as Independent Director of the Company. He has served as a director since July 2016. He is President, North America of GW Pharmaceuticals Inc., and President of Greenwich Biosciences, Inc., the U.S. subsidiary of GW Pharmaceuticals, spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli also served as a member of the board of directors of GW Pharmaceuticals Inc. from July 2015 to March 2017. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years. Prior to that, he served as Senior Vice President, U.S. Eye Care at Allergan. Prior to Allergan, Mr. Gangolli served in sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the United Kingdom. Our board of directors believes that Mr. Gangolli’s operating experience in the biopharmaceutical industry, experience at multiple public pharmaceutical companies and his expertise in the development and commercialization of specialty pharmaceutical products make him qualified to serve on our board of directors.
What is the salary of Julian Gangolli?
As the Independent Director of Revance Therapeutics Inc, the total compensation of Julian Gangolli at Revance Therapeutics Inc is 172,300$. There are 14 executives at Revance Therapeutics Inc getting paid more, with Mark Foley having the highest compensation of 17,190,400$.
How old is Julian Gangolli?
Julian Gangolli is 62, he's been the Independent Director of Revance Therapeutics Inc since 2016. There are 4 older and 11 younger executives at Revance Therapeutics Inc. The oldest executive at Revance Therapeutics Inc is Robert Byrnes, 75, who is the Independent Director.
What's Julian Gangolli's mailing address?
Julian's mailing address filed with the SEC is C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203.
Insiders trading at Revance Therapeutics Inc
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over 29,070,398$ worth of Revance Therapeutics Inc stock and bought 136,530 units worth 2,014,047$ . The most active insiders traders include Vlad Coric、Julian S Gangolli、Angus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of 83,132$. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth 9,090$.
What does Revance Therapeutics Inc do?
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
What does Revance Therapeutics Inc's logo look like?
Complete history of Mr. Gangolli stock trades at GW Pharmaceuticals、Revance Therapeutics Inc、Krystal Biotech Inc、Outlook Therapeutics Inc
Revance Therapeutics Inc executives and stock owners
Revance Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Foley,
President, Chief Executive Officer, Director -
Abhay Joshi,
Chief Operating Officer, President - R&D and Product Operations -
Tobin Schilke,
Chief Financial Officer -
Mark J. Foley,
CEO & Director -
Dustin Sjuts,
Chief Commercial Officer, Aesthetics & Therapeutics -
Dr. Abhay Joshi,
COO, Pres of R&D and Product Operations -
Dustin S. Sjuts,
Pres -
Tobin C. Schilke,
CFO & Principal Accounting Officer -
Chris Nolet,
Independent Director -
Jill Beraud,
Independent Director -
Angus Russell,
Independent Chairman of the Board -
Robert Byrnes,
Independent Director -
Philip Vickers,
Independent Director -
Phyllis Gardner,
Independent Director -
Julian Gangolli,
Independent Director -
Jeanie Herbert,
Sr. Director, Investor Relations -
Aubrey Rankin,
Director -
Dwight Moxie,
Senior Vice President, General Counsel, Corporate Secretary -
Azita Nejad,
Sr. VP of Technical Operations -
Justin Ford,
Sr. VP of HR & Head of People -
Taryn Conway,
VP of Marketing -
Jessica Serra,
Head of Investor Relations & ESG -
L Daniel Browne,
CEO and President -
James Walter Glasheen,
Director -
Ronald W Eastman,
Director -
Mark A Sr Prygocki,
Director -
Todd Erik Zavodnick,
CCO & President, -
Cyril Allouche,
Principal Accounting Officer -
Caryn Gordon Mc Dowell,
SVP, GC & Secretary -
Jacob Waugh,
Chief Scientific Officer -
Jonathan Tunnicliffe,
Director -
Ronald J Wooten,
Director -
Woodlands Health Ventures F...,
-
Arthur Peter Bertolino,
EVP and Chief Medical Officer -
Pharma Opportunities Fund I...,
-
Lauren P Silvernail,
CFO, Secretary & EVP Corp Dev. -
Curtis Ruegg,
EVP, Technical Operations -
Olivia C Ware,
Director -
Carey O Connor Kolaja,
Director -
Erica Jordan,
Chief Commercial Officer -
Vlad Coric,
Director